You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
艾迪藥業(688488.SH):預計上半年淨虧損880萬元-1320萬元
格隆匯 08-03 17:48

格隆匯8月3日丨艾迪藥業(688488.SH)公佈,預計公司2023年半年度營業收入約23,874.07萬元,較上年同期相比,將增加約16,496.20萬元,同比增加約223.59%;其中,抗HIV創新藥收入預計為3,282.66萬元,同比預計增加317.70%,人源蛋白粗品收入預計為17,161.87萬元,同比預計增加323.50%。

預計2023年半年度實現歸屬於母公司所有者的淨利潤約-1,320.00萬元到-880.00萬元,較上年同期相比,將減少虧損約5,499.16萬元至5,939.16萬元,虧損幅度同比下降約80.64%至87.10%;預計2023年半年度實現歸屬於母公司所有者扣除非經常性損益後的淨利潤約-3,000.00萬元到-2,000.00萬元,較上年同期相比,將減少虧損約4,570.25萬元至5,570.25萬元,虧損幅度同比下降約60.37%至73.58%。

抗HIV創新藥收入預計為3,282.66萬元,同比預計增加317.70%。基於艾諾韋林片療效確切、安全性好、副作用小等特點,結合醫保報銷的支付端優勢,艾諾韋林片的臨牀獲益逐步凸顯,隨着業務下沉逐級擴展到三四線城市與基層醫院,用藥人數及DTP藥房等藥品終端持續增加。為進一步提升藥物的可及範圍,惠及更多患者,公司於二季度開始逐步調整抗HIV創新藥商業化模式及銷售策略,採用學術推廣及多模式覆蓋,基於HIV用藥的慢病化特點及口服用藥的依從性優勢,用藥人數穩步增長的同時,患者亦表現出較好的粘性。截至報吿期末,已有29個省、自治區、直轄市的艾滋病患者受惠於艾諾韋林方案。

人源蛋白粗品收入預計為17,161.87萬元,同比預計增加323.50%。公司依靠在人源蛋白粗品方面的技術壁壘優勢、資源網絡優勢、規模生產優勢及原料品控優勢,在2022年人源蛋白粗品業務銷售規模縮減的局面下,不斷拓展海內外人源蛋白粗品市場,積極佈局上下游產業生態,報吿期內實現了較好的業績。人源蛋白業務的穩定健康發展,將為公司發展提供穩定的現金流,進一步增強自我造血能力,也為加大新藥研發投入提供堅實基礎。

報吿期內主營業務毛利較上年同期增加約8,700萬元;報吿期內因公司加大新藥推廣力度、加大引入運營及管理團隊等,本期銷售費用及管理費用合計支出較上年同期增加約2,700萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account